Search

Your search keyword '"Bruchfeld A"' showing total 1,784 results

Search Constraints

Start Over You searched for: Author "Bruchfeld A" Remove constraint Author: "Bruchfeld A"
1,784 results on '"Bruchfeld A"'

Search Results

1. FMM-Head: Enhancing Autoencoder-based ECG anomaly detection with prior knowledge

2. Individually tailored exercise in patients with postural orthostatic tachycardia syndrome related to post-COVID-19 condition – a feasibility study

4. Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment

5. Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients

6. The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population

7. Dysregulations in hemostasis, metabolism, immune response, and angiogenesis in post-acute COVID-19 syndrome with and without postural orthostatic tachycardia syndrome: a multi-omic profiling study

11. Residual radiological opacities correlate with disease outcomes in ICU-treated COVID-19

14. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

15. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

17. In-hospital cardiac arrest due to sepsis – Aetiologies and outcomes in a Swedish cohort study

18. Nomenclature in nephrology: preserving ‘renal’ and ‘nephro' in the glossary of kidney health and disease

21. Stress native T1 and native T2 mapping compared to myocardial perfusion reserve in long-term follow-up of severe Covid-19

22. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

24. European Working Group on SARS-CoV-2: Current Understanding, Unknowns, and Recommendations on the Neurological Complications of COVID-19.

25. Augmented thrombin formation is related to circulating levels of extracellular vesicles exposing tissue factor and citrullinated histone-3 in anti-neutrophil cytoplasmic antibody-associated vasculitides

26. Correlation of drug exposure and bacterial susceptibility with treatment response for Mycobacterium avium complex lung disease: protocol for a prospective observational cohort study

27. COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases

28. Identification of proteinase 3 autoreactive CD4+T cells and their T-cell receptor repertoires in antineutrophil cytoplasmic antibody–associated vasculitis

29. Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial

30. Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

31. Availability and costs of medicines for the treatment of tuberculosis in Europe

35. #1021 A phase 3 randomized controlled trial of ravulizumab in adult patients with IgA nephropathy

36. #3108 Rituximab in adult-onset IgA vasculitis

37. Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-Susceptible Patients with Multidrug-Resistant Tuberculosis

38. EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis— the European Renal Association (ERA) — Immunonephrology Working Group (ERA-IWG) perspective

41. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease

43. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

44. Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients

47. Attenuation of Torque teno viral load over time in kidney transplantation recipients treated with calcineurin inhibitors is mitigated after conversion to belatacept.

48. Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China.

49. Extrapulmonary Tuberculosis

Catalog

Books, media, physical & digital resources